The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | Andrew Davies: EHA 2020 lymphoma highlights
Andrew Davies, BSc, BM, MRCP, PhD, of the University of Southampton, Southampton, UK, explores exciting updates in lymphoma presented at EHA 2020. Dr Davies discusses the NCRI INCA study evaluating inotuzumab ozogamicin plus rituximab for diffuse large B-cell lymphoma (DLBCL) patients ineligible for R-CHOP chemotherapy, CAR T-cell therapies such as AUTO3 evaluated in the ALEXANDER study (NCT03287817) and recent trials investigating loncastuximab tesirine, an antibody-drug conjugate, in relapsed/refractory DLBCL. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
